TopGene

What TopGene does

TopGene (拓普基因), legally Guangzhou TopGene Technology Co., Ltd., is a precision oncology and genetic testing company headquartered in Guangzhou, China, founded in 2014. The company operates three clinical laboratories totaling approximately 4,000 square meters, equipped with high-throughput sequencing platforms including MGISEQ-2000 and NextSeq CN500 to provide genomic, transcriptomic, and epigenomic services. Its product portfolio spans three series: the breast cancer recurrence risk assessment series anchored by 普姿康™ (Puzikang™), a 21-gene RT-PCR assay that calculates recurrence risk score; the 洛氏伐® (Luoshifa®) targeted therapy guidance series, comprising a 19-gene lung cancer panel, a 180-gene solid tumor panel, and a 727-gene pan-cancer comprehensive panel using probe capture and NGS; and the hereditary tumor screening series, which includes 普全妍® (Puquanyan®, 103 genes across 35 cancer syndromes), 普姿妍® (Puziyan®, HRD score and 45 HRR-related genes including BRCA1/2), and 普媚妍® (Pumeiyan®, BRCA1/2 germline and somatic testing). The company's proprietary technical differentiators include UMI-based sequencing achieving 0.1% detection sensitivity at 20,000X depth, DNA+RNA dual-verification methodology to reduce fusion detection failure rates, and the AIvar CNN-based system for interpreting variants of uncertain significance (VUS), supported by the easyBRCA database of nearly 30,000 Chinese-population clinical samples.

The business model is dual-channel. The primary revenue stream is one-time clinical testing fees charged to hospitals, cancer centers, and clinics (B2B) and direct patients (B2C) who submit blood, saliva, or tissue samples through the company's CAP-, CLIA-, and ISO15189-certified laboratories; turnaround times range from 7 working days for the lung cancer assay to 14 natural days for BRCA testing. Parallel to the medical laboratory, TopGene sells a consumer health technology line through e-commerce channels, including 祝容颜 whitening and hydrating facial masks, 若尔® and 不老莓 aronia toothpastes, and the GENE PASSWORD NMN12000 supplement. Distribution is exclusively domestic to China; the company's website references a UK-domain International Website suggesting aspirational international presence but no operational overseas footprint is documented. The firm holds multiple quality and regulatory certifications (ISO9001, ISO14001, OHSAS18001, CAP, CLIA, ISO15189, NCCL, EMQN, GenQA) and its Zhongshan subsidiary has been certified as a National High-Tech Enterprise. Disclosed equity funding totals approximately $29 million across two rounds, one led by Matrix Partners China (December 2016, ~$14.4M) and one led by Guangzhou Yuexiu Industrial Investment Fund (August 2018, ~$14.6M); leadership comprises Chairman 由晓斌 (You Xiaobin) and General Manager 饶建梅 (Rao Jianmei).

Name

TopGene

Legal name

广州拓普基因科技有限公司

Website

https://topgene.cn

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

251–500 employees

Short description

TopGene (拓普基因) is a Guangzhou-based precision oncology company that operates clinical NGS laboratories delivering cancer gene panels, hereditary cancer screening, and targeted-therapy guidance testing to hospitals, clinics, and patients across China.

Ownership category

akta.pro rank

Product category

Cancer Genetic Testing Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Genetic testing services
• Cancer precision diagnostics
• Hereditary tumor screening
• Molecular pathology services
• Tumor genomic profiling

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Genetic Testing Services: Laboratory genetic testing services including cancer gene testing, hereditary tumor screening, and drug guidance testing for hospitals, clinics, and direct patients
2. Health Technology Products: Consumer health products including skincare (face masks), toothpaste, NMN supplements, and wellness products sold directly to consumers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

TopGene is a medical laboratory testing company that delivers cancer genetic testing services (breast cancer 21-gene RT-PCR assay, lung cancer 19-gene panel, solid tumor 180-gene panel, pan-cancer 727-gene NGS panel, hereditary tumor 103-gene panel, HRD scoring, and BRCA1/2 testing) through its CAP/CLIA-certified laboratories to hospitals, oncology clinics, and patients. The company also sells a line of consumer health technology products (NMN12000 supplement, facial masks, aronia toothpaste) directly to health-conscious consumers via its own e-commerce channels.

Product overview

TopGene is a genetic testing and precision medicine company offering a portfolio of medical diagnostic products organized into three main series: the breast cancer recurrence risk assessment series (普姿康™), the targeted medication guidance series (洛氏伐®), and the hereditary tumor screening series (普全妍®, 普姿妍®, 普媚妍®). The product portfolio includes the 普姿康 breast cancer 21-gene RT-PCR assay, the 洛氏伐® product line covering lung cancer (19 genes), solid tumors (180 genes), and pan-cancer panoramic testing (727 genes), and the hereditary tumor screening products covering BRCA1/2 and HRD testing. Additionally, the company offers a health technology product line including skincare (facial masks), oral care (toothpastes), and nutritional supplements (NMN12000). The company operates medical testing laboratories with sequencing platforms including MGISEQ-2000 and NextSeq CN500 for genomic, transcriptomic, and epigenomic services.

Differentiator

Problem solved

Functional benefit

Brands

• 普姿康™: Breast cancer 21 gene detection product using RT-PCR method for recurrence risk assessment
• 洛氏伐®Lung
• 洛氏伐®Small
• 洛氏伐®Target
• 普全妍®
• 普姿妍®
• 普媚妍®

Products and services

• Puzikang™ (普姿康™) Breast Cancer 21-Gene Recurrence Risk Assay RT-PCR-based 21-gene breast cancer recurrence risk assay measuring expression levels of 21 genes related to proliferation, invasion, and hormone signaling to compute the RS (recurrence score) for endocrine therapy versus chemotherapy benefit evaluation in Stage I–IIIa ER+/HER2- invasive breast cancer patients; 14 natural days turnaround.
• Luoshifa® Small (洛氏伐®Small) Solid Tumor 180-Gene Detection Panel NGS probe-capture panel covering 180 cancer-related genes including targeted therapy genes, immunotherapy biomarker MSI, and hereditary-related genes, applied to solid tumor samples for precision treatment selection across lung, breast, gastric, colorectal, liver, kidney, and other solid tumors.
• Luoshifa® Target (洛氏伐®Target) Pan-Cancer 727-Gene Detection NGS-based pan-cancer comprehensive gene detection covering 727 cancer-related genes spanning targeted therapy, immunotherapy, chemotherapy response, and hereditary genes; provides comprehensive molecular profiling for personalized treatment planning across all solid tumors; 11 natural days turnaround.
• Luoshifa® Lung (洛氏伐®Lung) Lung Cancer 19-Gene Targeted Therapy Panel Amplicon-based NGS lung cancer 19-gene detection panel for point mutations, small insertions/deletions, and rearrangements (fusions) related to lung cancer pathogenesis and targeted therapy drug selection; uses UMI tagging technology to achieve 0.1% low-frequency mutation detection sensitivity at 20,000X sequencing depth; 7 working days turnaround.
• Puquanyan® (普全妍®) Hereditary Tumor 103-Gene Detection Hereditary tumor gene detection panel covering 103 genes across 35 cancer types/syndromes, based on NCCN guidelines and authoritative database recommendations, supporting hereditary cancer risk assessment and early preventive screening for individuals with family history of cancer.
• Puziyan® (普姿妍®) Homologous Recombination Deficiency (HRD) Detection NGS-based HRD testing analyzing 45 HRR-related genes (including BRCA1/2) and calculating HRD score through LOH, LST, and TAI genomic instability indicators to identify platinum/PARP inhibitor sensitivity in ovarian, breast, prostate, pancreatic, and other solid tumors.
• Pumeiyan® (普媚妍®) BRCA1/2 Susceptibility Gene Detection BRCA1/2 germline genetic testing for breast, ovarian, pancreatic, and prostate cancer risk assessment; supports platinum chemotherapy and PARP inhibitor response prediction; powered by the proprietary easyBRCA Chinese-population database and AIvar CNN variant interpretation system; 14 natural days turnaround.
• GENE PASSWORD NMN12000 Supplement Nicotinamide Mononucleotide (NMN12000) anti-aging and cellular health supplement formulated as an NAD+ precursor, sold directly to consumers through the company's e-commerce storefront.
• Ruoer™ Biological Lysozyme Toothpaste (若尔™生物溶菌牙膏) Consumer oral care product — Ruoer™ biological lysozyme toothpaste — sold through the company's e-commerce storefront as part of the health technology product line.
• Ruoer™ Whitening and Radiant Toothpaste (若尔™凝白莹润牙膏) Consumer oral care product — Ruoer™ whitening and radiant toothpaste — sold through the company's e-commerce storefront as part of the health technology product line.
• Zhurongyan Whitening and Spot-Fading Facial Mask (祝容颜美白淡斑面膜) Skin whitening and spot-fading facial mask in the company's health technology product line, sold directly to consumers.
• Zhurongyan Moisturizing and Hydrating Facial Mask (祝容颜补水保湿面膜) Moisturizing and hydrating facial mask in the company's health technology product line, sold directly to consumers.
• Aronia Berry Toothpaste (不老莓牙膏) Aronia berry (black chokeberry) toothpaste in the company's health technology product line, sold directly to consumers.

Quantifiable outcome

• Detection of low-frequency mutations at 0.1% sensitivity with sequencing depth of 20,000X for lung cancer testing
• +2 more outcomes

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Three partnerships are on record, tiered minor.

• 祝江山不老莓红酒minorGTM or Marketing Partner · 24 May 2022Co-sponsorship of the Second Greater Bay Area Golf League with Zhu Jiangshan Black Aronia Wine. Joint marketing event at Dongguan Mission Hills Golf Club for the 6th Amateur Golf Super League qualifying rounds.
• Guangdong Provincial Committee of CCPITminorOthersVisit and exchange meeting with Guangdong Province Trade Promotion Committee International Liaison Department led by Minister He Xueguang, discussing cooperation and company capabilities.
• Yantai Haiyang City GovernmentminorOthersVisit by Haiyang City Standing Committee Liang Jingjun (Mayor) and other officials to TopGene headquarters for inspection and research on company development.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Novogene: Major Chinese genomics service provider with high-throughput sequencing platforms and oncology testing services, competing with TopGene across NGS-based cancer panels, hereditary testing, and clinical sequencing services.
• 3D Medicines: China-based next-generation precision oncology company providing NGS-based tumor profiling and companion diagnostics, directly competing in the same Chinese hospital oncology testing market as TopGene.
• OrigiMed: Chinese precision oncology company offering comprehensive NGS tumor profiling for solid tumor treatment guidance, directly comparable to TopGene's LuoShiTarget 727-gene pan-cancer product in target customers and use cases.
• Berry Genomics: China-based genetic testing company that initially focused on NIPT but expanded into oncology precision medicine - comparable target customers (hospitals/clinics) and overlapping test menu with TopGene.
• Annoroad Gene Technology: Chinese clinical genomics provider covering NIPT, reproductive health, and oncology NGS testing with broad panel offerings - similar product strategy and Chinese hospital channel to TopGene.
• Geneseeq Technology: China-based cancer genomics company offering NGS tumor profiling panels (including 458-gene and broader comprehensive assays) for solid tumor therapy guidance - directly comparable product, geography, and customer base to TopGene.
• Burning Rock Biotech: Chinese NGS-based cancer genomics company offering comprehensive tumor profiling panels for therapy selection, with significantly larger scale, public listing (NASDAQ), and established pharma partnerships - the closest and most relevant competitor to TopGene in cancer precision medicine.

Broad incumbents

• Guardant Health: US-based leader in liquid biopsy and comprehensive genomic profiling for cancer - a globally relevant incumbent whose blood-based tumor profiling approach and pharma CDx partnerships illustrate the strategic archetype TopGene is moving toward.
• Foundation Medicine: Roche-owned global leader in comprehensive genomic profiling for oncology whose FoundationOne CDx set the template for FDA-approved companion diagnostics - sets the bar for the precision-oncology testing franchise TopGene is building in China.
• BGI Genomics: Largest Chinese genomics company providing a broad portfolio of sequencing services across NIPT, oncology, reproductive health, and infectious disease - a broad incumbent whose oncology testing overlaps directly with TopGene's cancer NGS franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TopGene